Business Wire

H.I.G. WhiteHorse Europe Refinances Astek

30.5.2024 13:00:00 EEST | Business Wire | Press release

Share

H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G."), is pleased to announce that it has co-arranged a new €450 million financing package for Astek (the “Company” or the “Group”).

Founded in 1988 and controlled by its founder Jean-Luc Bernard, Astek is a global player in engineering and technology consulting. Headquartered in Boulogne-Billancourt, France, Astek operates in more than 20 countries with 8400 employees. Led by Julien Gavaldon since 2013, the Group has experienced significant growth as a result of organic activity and ten strategic acquisitions, over the past four years. The Group has developed leading market positions in its key geographies, notably in France, Poland, and Canada, in addition to growing positions in Northern and Western Europe, the Middle East, and Asia.

In 2021, H.I.G. WhiteHorse Europe acted as the sole arranger of a €170 million financing package used to refinance the Group’s existing loans and provide additional capital for growth. Having reached its business goals two years ahead of schedule, Astek is further strengthening its financial resources to support its plans of continued growth through a new senior-secured financing package of €450 million co-arranged by H.I.G. Additionally, Astek has welcomed its long-term investor, Intermediate Capital Group (“ICG”), as a strategic partner. ICG has provided an additional €110 million in equity financing to the Group.

Jean-Luc Bernard, Founder and Chairman of the Supervisory Board of Astek, said:“H.I.G. has been our partner since 2021 and I would like to thank them for their renewed confidence. The trust that has been built with H.I.G. has further strengthened the Group and Astek is now well-positioned for continued growth and profitability.”

Julien Gavaldon, Chief Executive Officer of Astek, said: “Thanks to our partnership with H.I.G., we have had a very successful growth trajectory, reaching our objectives two years ahead of schedule. We are determined to continue growing the Group, with the goal of exceeding 1 billion euros of turnover before 2027. H.I.G.’s renewed confidence in Astek, coupled with our new strategic partnership with ICG, positions us among the global leaders in digital transformation and technology consulting.”

Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said:“Astek is a remarkable company, led by a high-quality management team, and we are grateful for their renewed trust in H.I.G. WhiteHorse Europe. We are excited to continue supporting Jean-Luc Bernard, Julien Gavaldon, and Astek’s 8,400 employees as they embark on this exciting new phase of development.”

Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We deeply appreciate the renewed confidence shown by Jean-Luc Bernard and Julien Gavaldon in H.I.G. WhiteHorse Europe. Over the past years, Astek has achieved remarkable and consistent growth, establishing itself as a prominent global player. Its impressive market share gains, driven by approximately 20% organic growth (significantly exceeding market expansion) and a well-managed buy-and-build strategy, are a testimony to its success. We are delighted to continue supporting Astek as it embarks on this new chapter of development.”

About H.I.G. Capital

H.I.G. Capital is a leading global alternative investment firm with $62 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:

  • H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  • H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
  • H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
  • H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

* Based on total capital raised by H.I.G. Capital and affiliates.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pascal Meysson
Head of H.I.G. WhiteHorse Europe
pmeysson@hig.com

Charles Bourgeois
Managing Director
cbourgeois@hig.com

H.I.G. WhiteHorse Europe
10 Grosvenor Street
2nd Floor
London W1K 4QB
United Kingdom
P +44 (0) 207 318 5700
hig.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release

SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release

Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release

Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye